Simvastatin for Covid-19 Pneumonia (REMAP-CAP trial)
Simvastatin has anti-inflammatory properties, and while it isn’t an effective treatment for ARDS overall, it may improve outcomes in the subset of people with ARDS due to increased inflammation.
Observationally, patients who contracted Covid-19 pneumonia in the Wuhan and Delta eras while taking statins tended to have better outcomes than those not takin…
Keep reading with a 7-day free trial
Subscribe to PulmCCM to keep reading this post and get 7 days of free access to the full post archives.